Menaka Sarav is a Nephrology physician affiliated with Yale New Haven Hospital. OpenAlex indexes 35 publications with 1,061 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
20 York St
New Haven, CT 065103220
Telephone
203-737-8894Provider last certified this registry record 29 Apr 2024.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Travere Therapeutics, Inc.Program year20241 payment
- Amgen Inc.Program year20241 payment
- Aurinia Pharma U.S., Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
81.8%Loop diuretic20.6%Furosemide64%Torsemide27%Bumetanide9%Part D<11 patientsCalcium channel blocker19.5%Amlodipine Besylate91%Nifedipine Er9%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
11%Vitamin D3 Analog5.3%Calcitriol100%Part D≥17 patientsSGLT2 inhibitor2%Farxiga100%Part D<11 patients+ 2 more classes in this area
Other
7.2%Drugs for treatment of hyperkalemia and hyperphosphatemia4.5%Lokelma100%Part D≥12 patientsPhosphate Binder2.7%Sevelamer Carbonate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Declining Serum Albumin With Stable Body Mass Index: A Mortality Indicator in Predialysis Chronic Kidney Disease
Journal of Renal Nutrition
2025 - Integrating Lifestyle and Nutrition into CKD Care: Physician-Led Kidney Nutrition Program at Yale
Journal of the American Society of Nephrology
2025 - Declining Serum Albumin in the Shadow of Stable Body Mass Index: A Mortality Indicator in Predialysis CKD
Journal of the American Society of Nephrology
2024 - IMPLEMENTING ADHERENCE TO SGLT2I AND GLP1RA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FINDINGS FROM A PHARMACIST-DRIVEN CARDIODIABETES CLINIC PROGRAM
Journal of the American College of Cardiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Rohan Khera, MD
Yale New Haven Hospital
Michael Cecchini, MD
Yale New Haven Hospital
Jeptha Curtis, MD
Yale New Haven Hospital
Yongfei Wang
Yale New Haven Hospital
Andrew Levey, MD
Tufts Medical Center
Bertram Kasiske, MD
Hennepin Healthcare
Garabed Eknoyan, MD
Baylor College of Medicine
Lawrence Hunsicker, MD
University of Iowa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”